Massive infant study tests One-Shot shield against dangerous RSV
NCT ID NCT06325332
Summary
This study tested how well a single antibody shot (nirsevimab) protects infants from serious Respiratory Syncytial Virus (RSV) infections during their first RSV season. It involved nearly 50,000 infants to see if the shot reduced doctor visits, emergency room trips, and hospitalizations caused by RSV. The goal was to measure real-world effectiveness in preventing severe illness.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kaiser Permanente Northern California: Site number 0001
Oakland, California, 94612, United States
Conditions
Explore the condition pages connected to this study.